Table 6.

Pooled grade 3–4 adverse effects rate (grade 3–4 AEs%) and modified grade 3–4 adverse effects rate (grade 3–4 AEs%) in non‐small‐cell lung cancer (NSCLC) patients for included studies

Study		ORR (predeleted)		Study		ORR (postdeleted)
		Median	95% CI			Median	95% CI
	Total	20%	15–25%		Total	11%	7–14%
2013	Rizvi et al.	49%	34–64%	2014	Ramalingam et al.	15%	9–21%
2014	Antonia et al.	49%	35–63%	2014	Rizvi et al.	25%	10–40%
2014	Antonia et al.	45%	31–59%	2015	Bauer et al.	2%	0–4%
2014	Ramalingam et al.	15%	9–21%	2015	Borghaei et al.	10%	7–14%
2014	Rizvi et al.	25%	10–40%	2015	Brahmer et al.	7%	3–11%
2015	Bauer et al.	2%	0–4%	2015	Gettinger et al.	14%	8–20%
2015	Borghaei et al.	10%	7–14%	2015	Nishio et al.	16%	9–23%
2015	Brahmer et al.	7%	3–11%	2015	Rizvi et al.	17%	10–24%
2015	Gettinger et al.	14%	8–20%	2016	Brustugun et al.	5%	0–11%
2015	Nishio et al.	16%	9–23%	2016	Crino et al.	5%	3–8%
2015	Rizvi et al.	17%	10–24%	2016	Gettinger et al.	19%	8–30%
2016	Brustugun et al.	5%	0–11%	Overall (I 2  = 86.5%, P < 0.001); Egger's test (P < 0.001)
2016	Crino et al.	5%	3–8%
2016	Gettinger et al.	19%	8–30%
2016	Rizvi et al.	45%	32–58%
2017	Hellmann et al.	35%	24–48%
Overall (I 2  = 93.4%, P < 0.001); Egger's test (P < 0.001)